Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy
Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy
复制标题
DOI：
10.1097/cad.0b013e328349c7bb
复制
发表时间：
2011-11-01
影响因子：
2.3
通讯作者：
Salmon, Remy J.
中科院分区：
文献类型：
--
作者：
Kriegel, Irene;Cottu, Paul H.;Salmon, Remy J.
这项研究的目的是，在接受贝伐单抗治疗的转移性乳腺癌患者中，确定放置植入式静脉通路装置(VAD)后伤口裂开的发生率，并研究导管血栓形成的风险。这项研究纳入了14名麻醉师在2007年1月1日至2009年12月31日期间放置的所有VAD：273例接受贝伐单抗治疗的患者和4196例未接受贝伐单抗治疗的患者。贝伐单抗治疗组12例(4.76%)患者发生伤口裂开13例(4.76%)。所有的裂开病例都是在放置VAD后7天内开始贝伐单抗治疗的。150例患者在放置VAD后7d内开始贝伐单抗治疗(13例：8.6%)。从0到7天，裂开的风险是相同的。未接受贝伐单抗治疗的VAD伤口裂开发生率为0.19%(8/4197)(Fisher‘s检验，P
The aim of this study was to determine, in a population with metastatic breast cancer treated with bevacizumab therapy, the incidence of wound dehiscence after placement of an implantable venous access device (VAD) and to study the risk of catheter thrombosis. This study enrolled all VADs placed by 14 anesthetists between 1 January 2007 and 31 December 2009: 273 VADs in patients treated with bevacizumab therapy and 4196 VADs in patients not treated with bevacizumab therapy. In the bevacizumab therapy group, 13 cases of wound dehiscence occurred in 12 patients requiring removal of the VAD (4.76%). All cases of dehiscence occurred when bevacizumab therapy was initiated less than 7 days after VAD placement. Bevacizumab therapy was initiated less than 7 days after VAD placement in 150 cases (13 of 150: 8.6%). The risk of dehiscence was the same from 0 to 7 days. In parallel, the VAD wound dehiscence rate in patients not receiving bevacizumab therapy was eight of 4197 cases (0.19%) (Fisher's test significant, P